These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 9767622)
1. CYFRA 21-1 and ProGRP, tumor markers of lung cancer, are elevated in chronic renal failure patients. Nakahama H; Tanaka Y; Fujita Y; Fujii M; Sugita M Respirology; 1998 Sep; 3(3):207-10. PubMed ID: 9767622 [TBL] [Abstract][Full Text] [Related]
2. Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer. Pujol JL; Quantin X; Jacot W; Boher JM; Grenier J; Lamy PJ Lung Cancer; 2003 Feb; 39(2):131-8. PubMed ID: 12581564 [TBL] [Abstract][Full Text] [Related]
3. Triple test with tumor markers CYFRA 21.1, HE4, and ProGRP might contribute to diagnosis and subtyping of lung cancer. Korkmaz ET; Koksal D; Aksu F; Dikmen ZG; Icen D; Maden E; Onder S; Akbiyik F; Emri S Clin Biochem; 2018 Aug; 58():15-19. PubMed ID: 29729229 [TBL] [Abstract][Full Text] [Related]
4. Serum levels of five tumor markers for lung cancer in patients with chronic renal failure. Nomura F; Koyama A; Ishijima M; Takano S; Narita M; Nakai T Oncol Rep; 1998; 5(2):389-92. PubMed ID: 9468564 [TBL] [Abstract][Full Text] [Related]
5. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases. Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318 [TBL] [Abstract][Full Text] [Related]
6. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer. Molina R; Auge JM; Filella X; Viñolas N; Alicarte J; Domingo JM; Ballesta AM Anticancer Res; 2005; 25(3A):1773-8. PubMed ID: 16033098 [TBL] [Abstract][Full Text] [Related]
7. [Evaluation of CYFRA 21-1 and ProGRP in serum and bronchoalveolar lavage fluid of patients with benign lung disease]. Matsubara Y; Iwashita T; Ishimatsu Y; Shikuwa C; Kadota J; Kohno S Nihon Kokyuki Gakkai Zasshi; 2000 Sep; 38(9):659-64. PubMed ID: 11109801 [TBL] [Abstract][Full Text] [Related]
8. Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer. Holdenrieder S; von Pawel J; Dankelmann E; Duell T; Faderl B; Markus A; Siakavara M; Wagner H; Feldmann K; Hoffmann H; Raith H; Nagel D; Stieber P Clin Cancer Res; 2008 Dec; 14(23):7813-21. PubMed ID: 19047109 [TBL] [Abstract][Full Text] [Related]
10. Value of tumour and inflammatory markers in lung cancer. Oremek GM; Sauer-Eppel H; Bruzdziak TH Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794 [TBL] [Abstract][Full Text] [Related]
11. New and old biomarkers in the differential diagnosis of lung cancer: Pro-gastrin-releasing peptide in comparison with neuron-specific enolase, carcinoembryonic antigen, and CYFRA 21-1. Mauro C; Passerini R; Spaggiari L; Galetta D; Radice D; Lentati P; Sandri MT Int J Biol Markers; 2019 Jun; 34(2):163-167. PubMed ID: 30994045 [TBL] [Abstract][Full Text] [Related]
12. ProGRP and NSE in therapy monitoring in patients with small cell lung cancer. Wójcik E; Kulpa JK; Sas-Korczyńska B; Korzeniowski S; Jakubowicz J Anticancer Res; 2008; 28(5B):3027-33. PubMed ID: 19031951 [TBL] [Abstract][Full Text] [Related]
13. Enzyme-linked immunosorbent assay of pro-gastrin-releasing peptide for small cell lung cancer patients in comparison with neuron-specific enolase measurement. Yamaguchi K; Aoyagi K; Urakami K; Fukutani T; Maki N; Yamamoto S; Otsubo K; Miyake Y; Kodama T Jpn J Cancer Res; 1995 Jul; 86(7):698-705. PubMed ID: 7559089 [TBL] [Abstract][Full Text] [Related]
14. Usefulness of serum carboxy-terminal telopeptide of type I collagen (ICTP) as a marker of bone metastasis from lung cancer. Horiguchi T; Tachikawa S; Kondo R; Hirose M; Teruya S; Ishibashi A; Banno K Jpn J Clin Oncol; 2000 Apr; 30(4):174-9. PubMed ID: 10830985 [TBL] [Abstract][Full Text] [Related]
15. The diagnostic and prognostic value of ProGRP in lung cancer. Nisman B; Biran H; Ramu N; Heching N; Barak V; Peretz T Anticancer Res; 2009 Nov; 29(11):4827-32. PubMed ID: 20032442 [TBL] [Abstract][Full Text] [Related]
16. Pro-gastrin-releasing peptide in patients with benign and malignant diseases. Molina R; Auge JM; Alicarte J; Filella X; Viñolas N; Ballesta AM Tumour Biol; 2004; 25(1-2):56-61. PubMed ID: 15192313 [TBL] [Abstract][Full Text] [Related]
17. [The diagnostic significance of single or combination lung cancer-related serum biomarkers in high risk lung cancer patients]. Ni J; Guo Z; Zhang L Zhonghua Nei Ke Za Zhi; 2016 Jan; 55(1):25-30. PubMed ID: 26796649 [TBL] [Abstract][Full Text] [Related]
18. Human Epididymis Protein 4 (HE4) in Patients with Small-Cell Lung Cancer. Wojcik E; Tarapacz J; Rychlik U; Stasik Z; Sas-Korczynska B; Skotnicki P; Kulpa JK Clin Lab; 2016 Sep; 62(9):1625-1632. PubMed ID: 28164590 [TBL] [Abstract][Full Text] [Related]
19. Usefulness of serum tumor markers, including progastrin-releasing peptide, in patients with lung cancer: correlation with histology. Molina R; Augé JM; Bosch X; Escudero JM; Viñolas N; Marrades R; Ramírez J; Carcereny E; Filella X Tumour Biol; 2009; 30(3):121-9. PubMed ID: 19506400 [TBL] [Abstract][Full Text] [Related]
20. Complementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC). Shibayama T; Ueoka H; Nishii K; Kiura K; Tabata M; Miyatake K; Kitajima T; Harada M Lung Cancer; 2001 Apr; 32(1):61-9. PubMed ID: 11282430 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]